Business Context and Reporting Period
This Form 8-K Current Report, dated March 14, 2018, details a material definitive agreement entered into by Supernus Pharmaceuticals, Inc. The filing reports the company's entry into a Purchase Agreement for the offering and sale of convertible senior notes, with settlement occurring on March 19, 2018.
Key Financial Metrics and Transaction Details
- Debt Issuance: The company issued $402.5 million aggregate principal amount of 0.625% Convertible Senior Notes due 2023. This includes an initial $350 million offering plus a full exercise of a $52.5 million over-allotment option.
- Net Proceeds: Approximately $391.3 million was raised after deducting discounts, commissions, and estimated offering expenses.
- Interest Rate: 0.625% per annum, payable semi-annually in arrears starting October 1, 2018.
- Maturity Date: April 1, 2023.
- Conversion Terms: Initial conversion rate is 16.8545 shares per $1,000 principal amount (approx. $59.33 per share). Conversion is subject to specific conditions regarding stock price performance or corporate events.
- Use of Proceeds: Approximately $27.2 million was used to fund Convertible Note Hedge Transactions. The remaining balance is designated for acquisitions, investments, working capital, capital expenditures, and research and development.
Material Changes and Hedging Activities
In connection with the note offering, the company entered into privately negotiated convertible note hedge transactions and warrant transactions with Deutsche Bank AG, Bank of America, N.A., and JPMorgan Chase Bank. These transactions cover the number of shares underlying the notes.
- Hedge Transactions: Intended to reduce potential dilution upon conversion and offset cash payments exceeding the principal amount.
- Warrant Transactions: The company sold warrants to the counterparties with an initial strike price of $80.9063 per share. These are intended to offset the cost of the hedge transactions but may have a dilutive effect if the stock price exceeds the strike price.
Outlook, Risks, and Contingencies
The notes are senior, unsecured obligations, equal in right of payment to future senior unsecured indebtedness but structurally subordinated to subsidiary liabilities. The company cannot redeem the notes at its option before maturity. However, noteholders may require the company to repurchase the notes at a cash price equal to the principal plus accrued interest if a "fundamental change" occurs as defined in the Indenture. The filing does not provide specific revenue, profit, or cash flow metrics for the reporting period, as this is a transaction-specific report rather than a periodic financial statement.
Investor Verification Checklist
- Verify the exact terms of the "fundamental change" and "make-whole fundamental change" definitions in the attached Indenture (Exhibit 4.2) to understand repurchase triggers.
- Review the specific anti-dilution adjustment mechanisms in the Convertible Note Hedge and Warrant Transactions (Exhibits 10.1 through 10.12).
- Confirm the impact of the $27.2 million hedge cost on the company's immediate liquidity and remaining cash reserves.
- Monitor the company's stock price relative to the $59.33 conversion price and the $80.9063 warrant strike price to assess potential dilution scenarios.